Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Organisation › Details

Nosopharm SAS

Nosopharm is a biotechnology company specialized in the research and development of new antimicrobial molecules. Nosopharm discovered and developed NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. It has developed a unique expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins, the new class of antibiotics to which NOSO-502 belongs. Founded in 2009, Nosopharm is based in Lyon, France, and has a staff of eight. To date, the company has raised a total of €4.3M ($5.2M) in private equity and received €3.8M ($4.6M) in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER. *

 

Period Start 2009-02-01 established
Products Industry anti-infective drug
  Industry 2 antibiotic
Person Person Villain-Guillot, Philippe (Nosopharm 201703 President)
     
Region Region Lyon
  Country France
  Street 21 avenue Georges Pompidou
  City 69486 Lyon Cedex 3
  Tel +33-4-1171-6185
    Address record changed: 2024-01-05
     
Basic data Employees A: 1 to 10 (2018-02-12)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-03-30

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Nosopharm SAS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x300px




» top